{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:50:50Z","timestamp":1794091850320,"version":"4.8.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00603","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T08:10:29Z","timestamp":1746173429000},"page":"e00603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Age on Switching or Stopping Disease Modifying Therapies in Multiple Sclerosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Areeba","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ncl.2010.12.009","article-title":"The immunopathophysiology of multiple sclerosis","volume":"29","author":"Wu","year":"2011","journal-title":"Neurol Clin"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1234572","article-title":"Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration","volume":"4","author":"Thakolwiboon","year":"2023","journal-title":"Front Aging"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00603_bib5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00603_bib6","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1177\/1352458518800815","article-title":"Age is a critical determinant in recovery from multiple sclerosis relapses","volume":"25","author":"Conway","year":"2019","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib7","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology [Internet]"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00603_bib8","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1177\/1352458517729461","article-title":"Clinical trial design for progressive MS trials","volume":"23","author":"Pardini","year":"2017","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420969016","article-title":"Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00603_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurot.2025.e00603_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103308","article-title":"Prescribing of disease modifying agents in older adults with multiple sclerosis","volume":"57","author":"Talwar","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00603_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00603_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2018.06.001","article-title":"Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy","volume":"391","author":"Kister","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00603_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.msard.2019.07.021","article-title":"Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes","volume":"35","author":"Yano","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping disease-modifying treatments in multiple sclerosis: a systematic review and meta-analysis of real-world studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00603_bib21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/ene.14705","article-title":"Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00603_bib22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 Years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol [Internet]."},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.3062","article-title":"Differential diagnosis of suspected multiple sclerosis in pediatric and late-onset populations: a review","author":"Hua","year":"2024","journal-title":"JAMA Neurol [Internet]"},{"key":"10.1016\/j.neurot.2025.e00603_bib25","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial","author":"Coerver","year":"2024","journal-title":"JAMA Neurol [Internet]"},{"key":"10.1016\/j.neurot.2025.e00603_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00603_bib28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/1352458520952036","article-title":"De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis","volume":"27","author":"Disanto","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00603_bib29","article-title":"De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: a pilot study","volume":"92","author":"Sacco","year":"2024","journal-title":"Mult Scler Relat Disord [Internet]"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/CPJ.0000000000000434","article-title":"Effectiveness of alternative dose fingolimod for multiple sclerosis","volume":"8","author":"Longbrake","year":"2018","journal-title":"Neurol Clin Pract"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"Van Lierop","year":"2022","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00603_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00603_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103490","article-title":"Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years","volume":"58","author":"Disanto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00603_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102572","article-title":"Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis","volume":"46","author":"Leist","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00603_bib36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/1352458520964778","article-title":"Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression","volume":"27","author":"Prosperini","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00603_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00603_bib38","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJMc1415408","article-title":"PML in a patient with lymphocytopenia treated with dimethyl fumarate","volume":"372","author":"Rosenkranz","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.neurot.2025.e00603_bib39","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJMc1215357","article-title":"PML in a patient treated with dimethyl fumarate from a compounding pharmacy","volume":"368","author":"Van Oosten","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00603_bib40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0b013e3182a43e6d","article-title":"In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection","volume":"81","author":"Martin-Blondel","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00603_bib41","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1399-0039.2007.00891.x","article-title":"Immunosenescence: deficits in adaptive immunity in the elderly","volume":"70","author":"Hakim","year":"2007","journal-title":"Tissue Antigens"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00603_bib43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1177\/1352458520977132","article-title":"Expanding spectrum of opportunistic infections associated with dimethyl fumarate","volume":"27","author":"Kim","year":"2021","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1212\/CPJ.0000000000000800","article-title":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS","volume":"10","author":"Chan","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00603_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00603_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib47","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000614","article-title":"Lymphocyte counts and infection rates: long-term fingolimod treatment in primary progressive MS","volume":"6","author":"Fox","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib48","article-title":"Risk factors for fingolimod-induced lymphopenia in multiple sclerosis","volume":"4","author":"Ohtani","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.neurot.2025.e00603_bib49","article-title":"Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study","author":"Zecca","year":"2017","journal-title":"Mult Scler J"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib50","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.neurot.2025.e00603_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221133163","article-title":"S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review","volume":"15","author":"Constantinescu","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00603_bib52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2015.03.022","article-title":"Severe disease reactivation in four patients with relapsing\u2013remitting multiple sclerosis after fingolimod cessation","volume":"282","author":"Berger","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib53","first-page":"12","article-title":"Factors predictive of severe multiple sclerosis disease reactivation after fingolimod cessation","volume":"23","author":"Uygunoglu","year":"2018","journal-title":"Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00603_bib54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-019-00804-6","article-title":"Severe exacerbation of multiple sclerosis following withdrawal of fingolimod","volume":"39","author":"Fragoso","year":"2019","journal-title":"Clin Drug Invest"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pjnns.2017.01.006","article-title":"Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod","volume":"51","author":"Cz\u0142onkowska","year":"2017","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.neurot.2025.e00603_bib56","article-title":"Extensive multiple sclerosis reactivation after switching from fingolimod to rituximab","volume":"2018","author":"Holm\u00f8y","year":"2018","journal-title":"Case Rep Neurol Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib57","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00415-019-09195-2","article-title":"Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe","volume":"266","author":"Alcal\u00e1","year":"2019","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib58","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00415-021-10708-1","article-title":"Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration","volume":"269","author":"Ferraro","year":"2022","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib59","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200231","article-title":"Effect of prior treatment with fingolimod on early and late response to rituximab\/ocrelizumab in patients with multiple sclerosis","volume":"11","author":"Graille-Avy","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00603_bib60","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10_supplement","key":"10.1016\/j.neurot.2025.e00603_bib61","doi-asserted-by":"crossref","first-page":"P2","DOI":"10.1212\/WNL.82.10_supplement.P2.194","article-title":"Teriflunomide treatment is not associated with increased risk of infections: pooled data from the teriflunomide development program (P2.194)","volume":"82","author":"Singer","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib62","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40263-015-0299-y","article-title":"Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis","volume":"30","author":"Chan","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurot.2025.e00603_bib64","series-title":"Aubagio(R) [package insert] [Internet]","year":"2012"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00603_bib65","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology [Internet]"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00603_bib66","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.neurot.2025.e00603_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00603_bib69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expet Opin Drug Saf"},{"issue":"19","key":"10.1016\/j.neurot.2025.e00603_bib70","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00603_bib71","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib75","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00603_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00603_bib77","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab: a multicentric Italian\u2013Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib78","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","article-title":"Discontinuation and dose reduction of rituximab in relapsing\u2013remitting multiple sclerosis","volume":"268","author":"Boremalm","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117501","article-title":"Personalizing ocrelizumab treatment in Multiple Sclerosis: what can we learn from Sars-Cov2 pandemic?","volume":"427","author":"Tazza","year":"2021","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00603_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent Registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00603_bib83","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00603_bib84","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00603_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib86","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1212\/CPJ.0000000000000809","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/imt.14.7","article-title":"Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis","volume":"6","author":"Hersh","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.neurot.2025.e00603_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00603_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102717","article-title":"Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years","volume":"49","author":"Bass","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00603_bib90","series-title":"Lemtrada(R) [package insert] [Internet]","year":"2001"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00603_bib91","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7224\/1537-2073.2014-076","article-title":"Medications are associated with falls in people with multiple sclerosis","volume":"17","author":"Cameron","year":"2015","journal-title":"Int J MS Care"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00603_bib92","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib93","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1352458516650512","article-title":"Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course","volume":"23","author":"Conway","year":"2017","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib94","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/brain\/awaa255","article-title":"Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships","volume":"143","author":"Geraldes","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00603_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bandc.2020.105650","article-title":"The effects of aging and disease duration on cognition in multiple sclerosis","volume":"146","author":"Tremblay","year":"2020","journal-title":"Brain Cogn"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib96","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ncl.2023.07.003","article-title":"Clinical and treatment considerations for the pediatric and aging patients with multiple sclerosis","volume":"42","author":"Siddiqui","year":"2024","journal-title":"Neurol Clin"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264557","article-title":"Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: a systematic review and meta-analysis of exercise intervention trials","volume":"17","author":"Shobeiri","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00603_bib98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41577-019-0177-9","article-title":"Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?","volume":"19","author":"Duggal","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00603_bib99","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1038\/s41598-021-86593-5","article-title":"Exercise rapidly alters proteomes in mice following spinal cord demyelination","volume":"11","author":"Lozinski","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00603_bib100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1756285611430719","article-title":"Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?","volume":"5","author":"Dalgas","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib101","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hch105","article-title":"What drives quality of life in multiple sclerosis?","volume":"97","author":"Hemmett","year":"2004","journal-title":"QJM: Int J Med"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00603_bib102","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.phm.0000237871.91829.30","article-title":"Concordance in goal setting between patients with multiple sclerosis and their rehabilitation team","volume":"85","author":"Bloom","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.neurot.2025.e00603_bib103","series-title":"Clinical neurology","first-page":"348","year":"2009"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00603_bib104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7224\/1537-2073.2013-023","article-title":"A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis","volume":"16","author":"Goodman","year":"2014","journal-title":"Int J MS Care"},{"issue":"7\u20138","key":"10.1016\/j.neurot.2025.e00603_bib105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1345\/aph.1Q714","article-title":"Dalfampridine: a medication to improve walking in patients with multiple sclerosis","volume":"46","author":"Pikoulas","year":"2012","journal-title":"Ann Pharmacother"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:01:11Z","timestamp":1755090071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000819"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00603","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Age on Switching or Stopping Disease Modifying Therapies in Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00603"}}